156 related articles for article (PubMed ID: 17374707)
21. Tumour induced osteomalacia.
Masood MQ; Ram N; Ali SA
J Pak Med Assoc; 2015 Feb; 65(2):220-2. PubMed ID: 25842564
[TBL] [Abstract][Full Text] [Related]
22. Tumor-induced osteomalacia originating from the temporal bone: a case report.
Kobayashi K; Nakao K; Kawai K; Ito K; Hukumoto S; Asakage T; Oota S; Motoi R
Head Neck; 2011 Jul; 33(7):1072-5. PubMed ID: 20146335
[TBL] [Abstract][Full Text] [Related]
23. Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia.
Habra MA; Jimenez C; Huang SC; Cote GJ; Murphy WA; Gagel RF; Hoff AO
Endocr Pract; 2008 Dec; 14(9):1108-14. PubMed ID: 19158050
[TBL] [Abstract][Full Text] [Related]
24. Surgical treatment of tumor-induced osteomalacia: a retrospective review of 40 cases with extremity tumors.
Sun ZJ; Jin J; Qiu GX; Gao P; Liu Y
BMC Musculoskelet Disord; 2015 Feb; 16():43. PubMed ID: 25879543
[TBL] [Abstract][Full Text] [Related]
25. Levels and dynamic changes of serum fibroblast growth factor 23 in hypophosphatemic rickets/osteomalacia.
Xia WB; Jiang Y; Li M; Xing XP; Wang O; Hu YY; Zhang HB; Liu HC; Meng XW; Zhou XY
Chin Med J (Engl); 2010 May; 123(9):1158-62. PubMed ID: 20529556
[TBL] [Abstract][Full Text] [Related]
26. Tumor-induced hypophosphatemic osteomalacia diagnosed by the combinatory procedures of magnetic resonance imaging and venous sampling for FGF23.
Nasu T; Kurisu S; Matsuno S; Tatsumi K; Kakimoto T; Kobayashi M; Nakano Y; Wakasaki H; Furuta H; Nishi M; Sasaki H; Suzuki H; Ito N; Fukumoto S; Nanjo K
Intern Med; 2008; 47(10):957-61. PubMed ID: 18480582
[TBL] [Abstract][Full Text] [Related]
27. Preoperative tumor localization by means of venous sampling for fibroblast growth factor-23 in a patient with tumor-induced osteomalacia.
Westerberg PA; Olauson H; Toss G; Wikström B; Morales O; Linde T; Jonsson K; Ljunggren O; Larsson TE
Endocr Pract; 2008 Apr; 14(3):362-7. PubMed ID: 18463045
[TBL] [Abstract][Full Text] [Related]
28. Comparison of two assays for fibroblast growth factor (FGF)-23.
Ito N; Fukumoto S; Takeuchi Y; Yasuda T; Hasegawa Y; Takemoto F; Tajima T; Dobashi K; Yamazaki Y; Yamashita T; Fujita T
J Bone Miner Metab; 2005; 23(6):435-40. PubMed ID: 16261449
[TBL] [Abstract][Full Text] [Related]
29. RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia.
Bahrami A; Weiss SW; Montgomery E; Horvai AE; Jin L; Inwards CY; Folpe AL
Am J Surg Pathol; 2009 Sep; 33(9):1348-54. PubMed ID: 19609206
[TBL] [Abstract][Full Text] [Related]
30. Effects of tumor-induced osteomalacia on the bone mineralization process.
Nawrot-Wawrzyniak K; Varga F; Nader A; Roschger P; Sieghart S; Zwettler E; Roetzer KM; Lang S; Weinkamer R; Klaushofer K; Fratzl-Zelman N
Calcif Tissue Int; 2009 Apr; 84(4):313-23. PubMed ID: 19219382
[TBL] [Abstract][Full Text] [Related]
31. Osteomalacia induced by a phosphaturic mesenchymal tumor secreting fibroblast growth factor 23.
Nagae K; Uchi H; Ito T; Moroi Y; Oda Y; Furue M
Eur J Dermatol; 2015 Apr; 25(2):199-200. PubMed ID: 25788099
[No Abstract] [Full Text] [Related]
32. [Oncogenic osteomalacia: the role of the phosphatonins. Diagnostic usefulness of the Fibroblast Growth Factor 23 measurement in one patient].
Dupond JL; Magy N; Mahammedi M; Prie D; Gil H; Meaux-Ruault N; Kantelip B
Rev Med Interne; 2005 Mar; 26(3):238-41. PubMed ID: 15777586
[TBL] [Abstract][Full Text] [Related]
33. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women.
Burnett SM; Gunawardene SC; Bringhurst FR; Jüppner H; Lee H; Finkelstein JS
J Bone Miner Res; 2006 Aug; 21(8):1187-96. PubMed ID: 16869716
[TBL] [Abstract][Full Text] [Related]
34. Clinical and bone density outcomes of tumor-induced osteomalacia after treatment.
Umphrey LG; Whitaker MD; Bosch EP; Cook CB
Endocr Pract; 2007 Sep; 13(5):458-62. PubMed ID: 17872346
[TBL] [Abstract][Full Text] [Related]
35. Resolution of severe, adolescent-onset hypophosphatemic rickets following resection of an FGF-23-producing tumour of the distal ulna.
Ward LM; Rauch F; White KE; Filler G; Matzinger MA; Letts M; Travers R; Econs MJ; Glorieux FH
Bone; 2004 May; 34(5):905-11. PubMed ID: 15121023
[TBL] [Abstract][Full Text] [Related]
36. Bone turnover and the osteoprotegerin-RANKL pathway in tumor-induced osteomalacia: a longitudinal study of five cases.
Rendina D; De Filippo G; Tauchmanovà L; Insabato L; Muscariello R; Gianfrancesco F; Esposito T; Cioffi M; Colao A; Strazzullo P; Mossetti G
Calcif Tissue Int; 2009 Oct; 85(4):293-300. PubMed ID: 19763378
[TBL] [Abstract][Full Text] [Related]
37. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
Fukumoto S; Yamashita T
N Engl J Med; 2003 Jul; 349(5):505-6; author reply 505-6. PubMed ID: 12892105
[No Abstract] [Full Text] [Related]
38. Determination of fibroblast growth factor 23.
Heijboer AC; Levitus M; Vervloet MG; Lips P; ter Wee PM; Dijstelbloem HM; Blankenstein MA
Ann Clin Biochem; 2009 Jul; 46(Pt 4):338-40. PubMed ID: 19564163
[TBL] [Abstract][Full Text] [Related]
39. Clinical Characteristics and Surgical Outcomes of Sinonasal Lesions Associated With Tumor-Induced Osteomalacia.
Zhu Z; Xia W; Qi F; Wang W; Wang X; Zha Y; Li F; Jing H; Wang P; Lv W
Otolaryngol Head Neck Surg; 2021 Jul; 165(1):223-231. PubMed ID: 33290165
[TBL] [Abstract][Full Text] [Related]
40. [Osteomalacia due to phosphate deficiency caused by a tumor. Focus on FGF23 in physiology and clinic].
Westerberg PA; Linde T; Ljunggren O
Lakartidningen; 2012 Aug 8-21; 109(32-33):1414-6. PubMed ID: 22953430
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
